Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults over 70 years old.
Abstract
The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults age ≥70 with AML. However, while potentially curative, non-relapse mortality and relapse represent the main causes of treatment failure, highlighting the importance of refining both patient selection and transplant strategies. At the same time, continuously evolving non-transplant therapies and transplant technologies mandate prospective trials (re-)examining the role of allo-HCT and its optimal delivery.
Citations
Altmetric:
Date
2024-09-06
Type
Article
Subject
Haematology
Collections
Citation
Walter RB, Potter V, Craddock C. Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults over 70 years old. Blood. 2024 Sep 6:blood.2024024247. doi: 10.1182/blood.2024024247. Epub ahead of print
Journal / Source Title
Blood
DOI
10.1182/blood.2024024247
PMID
39241195
Publisher
Elsevier
Publisher’s URL
https://www.sciencedirect.com/journal/blood